Virginia Ispine Physicians, PC — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$148,537	28
2024	Research	$70,359	22
2023	Research	$161,372	16
2021	Research	$34,810	2

Breakdown

Who paid Research payments · program years 2021–2025

SPR Therapeutics, Inc $229,239 43 payments
Mesoblast, Inc. $117,257 10 payments
Seikagaku Corporation $34,810 2 payments
Pacira Pharmaceuticals Incorporated $21,799 8 payments
Novartis Pharmaceuticals Corporation $11,972 5 payments

Studies the money was for Research payments · program years 2021–2025

A Randomized, Controlled, Multicenter Trial of Percutaneous Peripheral Nerve Stimulation (PNS) for the Treatment of Back Pain $221,904 40 payments
Msb-Dr004 $117,257 10 payments
6603/1133 $34,810 2 payments
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity $21,799 8 payments
A 5-Year, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Assessing the Efficacy, Safety, and Tolerability of Intra-Articular Regimens of Lna043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis $11,011 3 payments
A Post-Market Study of Percutaneous Peripheral Nerve Stimulation (PNS) for the $7,335 3 payments
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy $961 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.